Perinatal administration of Saccharomyces cerevisiae UFMG A-905 prevents asthma development in the offspring of mice.

IF 3 4区医学 Q2 MICROBIOLOGY Beneficial microbes Pub Date : 2024-09-27 DOI:10.1163/18762891-bja00044

C M Sandy, C C Guimarães, V M B Fonseca, J R Nicoli, F S Martins, M C Borges

{"title":"Perinatal administration of Saccharomyces cerevisiae UFMG A-905 prevents asthma development in the offspring of mice.","authors":"C M Sandy, C C Guimarães, V M B Fonseca, J R Nicoli, F S Martins, M C Borges","doi":"10.1163/18762891-bja00044","DOIUrl":null,"url":null,"abstract":"<p><p>Asthma prevalence has been increasing in communities that become more urbanised. Our previous results showed that Saccharomyces cerevisiae UFMG A-905 prevented the development of asthma symptoms and characteristics in a dose-dependent manner. Perinatal programming theory proposes that early exposure to some stimuli may have a protective effect in adult life. The aim of this study was to evaluate the effects of perinatal administration of S. cerevisiae UFMG A-905 in the prevention of asthma in the offspring of mice. S. cerevisiae UFMG A-905 was cultured in YPD broth medium and administered to three groups of mice: before conception, during gestation and lactation (CGL group); during gestation and lactation (GL group); and only during lactation (L group). The offspring of these animals were sensitised and challenged with ovalbumin. Two control groups received saline in the same periods. After, in vivo measurements of airway hyperresponsiveness (AHR) were performed. Total and differential cell count in bronchoalveolar lavage (BAL); ELISA for interleukin (IL)-4, IL-5, IL-10, IL-13, and IL-17A in the lung homogenate or BAL; and ELISA for ovalbumin (OVA)-specific immunoglobulin E (IgE) were performed. The animals of the CGL, GL, and L group, when compared to the OVA group, presented a significant reduction of AHR ( P < 0.01), levels of IL-5 ( P < 0.001) in BAL, and IL-4 ( P < 0.05) and IL-13 ( P < 0.01) in the lung homogenate. Serum IgE levels were significantly higher ( P < 0.05) in CGL and GL groups when compared to the OVA group, but not in the L group. Only in the group L, there was a significant decrease in the number of total cells ( P < 0.01) and eosinophils ( P < 0.05). Perinatal administration of S. cerevisiae UFMG A-905 prevented the development of asthma-like characteristics and may be an option for asthma management. The protective effects on the offspring were more prominent when the yeast was given during lactation.</p>","PeriodicalId":8834,"journal":{"name":"Beneficial microbes","volume":" ","pages":"1-10"},"PeriodicalIF":3.0000,"publicationDate":"2024-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Beneficial microbes","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1163/18762891-bja00044","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MICROBIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Asthma prevalence has been increasing in communities that become more urbanised. Our previous results showed that Saccharomyces cerevisiae UFMG A-905 prevented the development of asthma symptoms and characteristics in a dose-dependent manner. Perinatal programming theory proposes that early exposure to some stimuli may have a protective effect in adult life. The aim of this study was to evaluate the effects of perinatal administration of S. cerevisiae UFMG A-905 in the prevention of asthma in the offspring of mice. S. cerevisiae UFMG A-905 was cultured in YPD broth medium and administered to three groups of mice: before conception, during gestation and lactation (CGL group); during gestation and lactation (GL group); and only during lactation (L group). The offspring of these animals were sensitised and challenged with ovalbumin. Two control groups received saline in the same periods. After, in vivo measurements of airway hyperresponsiveness (AHR) were performed. Total and differential cell count in bronchoalveolar lavage (BAL); ELISA for interleukin (IL)-4, IL-5, IL-10, IL-13, and IL-17A in the lung homogenate or BAL; and ELISA for ovalbumin (OVA)-specific immunoglobulin E (IgE) were performed. The animals of the CGL, GL, and L group, when compared to the OVA group, presented a significant reduction of AHR ( P < 0.01), levels of IL-5 ( P < 0.001) in BAL, and IL-4 ( P < 0.05) and IL-13 ( P < 0.01) in the lung homogenate. Serum IgE levels were significantly higher ( P < 0.05) in CGL and GL groups when compared to the OVA group, but not in the L group. Only in the group L, there was a significant decrease in the number of total cells ( P < 0.01) and eosinophils ( P < 0.05). Perinatal administration of S. cerevisiae UFMG A-905 prevented the development of asthma-like characteristics and may be an option for asthma management. The protective effects on the offspring were more prominent when the yeast was given during lactation.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

围产期服用酿酒酵母 UFMG A-905 可预防小鼠后代哮喘的发生。

随着城市化进程的加快，哮喘发病率也在不断上升。我们之前的研究结果表明，酵母菌 UFMG A-905 能以剂量依赖的方式防止哮喘症状和特征的发展。围产期编程理论认为，早期接触某些刺激可能会对成年后的生活产生保护作用。本研究的目的是评估围产期服用 S. cerevisiae UFMG A-905 对预防小鼠后代哮喘的影响。在 YPD 肉汤培养基中培养 S. cerevisiae UFMG A-905，并给三组小鼠施用：受孕前、妊娠期和哺乳期（CGL 组）；妊娠期和哺乳期（GL 组）；仅哺乳期（L 组）。这些动物的后代接受卵清蛋白的致敏和挑战。两个对照组在同一时期接受生理盐水。之后，对气道高反应性（AHR）进行体内测量。对支气管肺泡灌洗液（BAL）中的总细胞数和差异细胞数、肺匀浆或BAL中的白细胞介素（IL）-4、IL-5、IL-10、IL-13和IL-17A进行了ELISA检测，并对卵清蛋白（OVA）特异性免疫球蛋白E（IgE）进行了ELISA检测。与OVA组相比，CGL、GL和L组动物的AHR（P＜0.01）、BAL中IL-5（P＜0.001）、肺匀浆中IL-4（P＜0.05）和IL-13（P＜0.01）水平均显著降低。与OVA组相比，CGL组和GL组的血清IgE水平明显升高（P < 0.05），但L组没有升高。只有 L 组的总细胞数（P < 0.01）和嗜酸性粒细胞数（P < 0.05）明显减少。围产期服用 S. cerevisiae UFMG A-905 可预防哮喘样特征的发展，可能是治疗哮喘的一种选择。在哺乳期服用酵母菌对后代的保护作用更为显著。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Beneficial microbes MICROBIOLOGY-NUTRITION & DIETETICS

CiteScore

7.90

自引率

1.90%

发文量

审稿时长

>12 weeks

期刊介绍： Beneficial Microbes is a peer-reviewed scientific journal with a specific area of focus: the promotion of the science of microbes beneficial to the health and wellbeing of man and animal. The journal contains original research papers and critical reviews in all areas dealing with beneficial microbes in both the small and large intestine, together with opinions, a calendar of forthcoming beneficial microbes-related events and book reviews. The journal takes a multidisciplinary approach and focuses on a broad spectrum of issues, including safety aspects of pro- & prebiotics, regulatory aspects, mechanisms of action, health benefits for the host, optimal production processes, screening methods, (meta)genomics, proteomics and metabolomics, host and bacterial physiology, application, and role in health and disease in man and animal. Beneficial Microbes is intended to serve the needs of researchers and professionals from the scientific community and industry, as well as those of policy makers and regulators. The journal will have five major sections: * Food, nutrition and health * Animal nutrition * Processing and application * Regulatory & safety aspects * Medical & health applications In these sections, topics dealt with by Beneficial Microbes include: * Worldwide safety and regulatory issues * Human and animal nutrition and health effects * Latest discoveries in mechanistic studies and screening methods to unravel mode of action * Host physiology related to allergy, inflammation, obesity, etc. * Trends in application of (meta)genomics, proteomics and metabolomics * New developments in how processing optimizes pro- & prebiotics for application * Bacterial physiology related to health benefits